Jared Ryan Kelly Buys 29,500 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) insider Jared Ryan Kelly bought 29,500 shares of the business’s stock in a transaction that occurred on Thursday, February 12th. The shares were acquired at an average cost of C$1.16 per share, for a total transaction of C$34,220.00. Following the completion of the purchase, the insider owned 109,000 shares in the company, valued at C$126,440. This trade represents a 37.11% increase in their ownership of the stock.

Jared Ryan Kelly also recently made the following trade(s):

• On Wednesday, February 11th, Jared Ryan Kelly acquired 5,600 shares of Oncolytics Biotech stock. The shares were bought at an average cost of C$1.15 per share, for a total transaction of C$6,440.00.

Oncolytics Biotech Price Performance

The business’s 50-day moving average is C$14.90 and its 200-day moving average is C$13.02. Oncolytics Biotech Inc. has a twelve month low of C$0.44 and a twelve month high of C$2.08. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99. The stock has a market capitalization of C$1.50 billion, a price-to-earnings ratio of -40.27 and a beta of 0.80.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings data on Wednesday, November 12th. The company reported C($0.14) earnings per share for the quarter. As a group, analysts anticipate that Oncolytics Biotech Inc. will post -0.41 earnings per share for the current year.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.